DURHAM, N.C., Dec. 8 /PRNewswire/ -- Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint. HTI was assisted in the successful execution of this trial by Cato Research Ltd., a global contract research and development organization ("CRO") that is affiliated with Cato BioVentures.
"HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company," said Daniel Pharand, CEO of HTI.
Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking 3 or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.
"We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension," said Allen Cato, M.D., Ph.D., CEO of Cato Research Ltd.
HTI obtained the core technology through an exclusive patent a license agreement with the University of Alabama Research Foundation ("UABRF").
About Hemodynamic Therapeutics, Inc.
HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVentures and its contract research and development affiliate, Cato Research Ltd., HTI executed its Phase 2 development program for HTI-101, a novel small molecule combination therapy for obesity-related hypertension (ORH), one of the world's fastest growing cardiovascular disease markets. For more information, visit the company's web site at http://www.hemodynamictx.com.
About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research Ltd. For over 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park, Montreal, and Silicon Valley. For more information, visit the company's web site at http://www.catobioventures.com.
About Cato Research Ltd.
Founded in 1988 by Allen Cato, M.D., Ph.D., and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a global, full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, medical device, and medical diagnostic industries. With a staff of more than 300 employees located in the United States, Europe, Canada, Israel, India and South Africa, Cato Research's services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. For more information, visit the company's web site at http://www.cato.com.
SOURCE Hemodynamic Therapeutics, Inc.
|SOURCE Hemodynamic Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved